Organization Profile
Founded in August 2002, IPMG is a non-profit association of international R&D-based pharmaceutical companies operating in Indonesia. IPMG currently represents 24 companies that are committed to researching, developing, manufacturing, and marketing safe, high quality medicines.
IPMG communicates the role and contribution of R&D-based pharmaceutical manufacturers in helping people improve their quality of life as well as pushing for an advancement of an effective and integrated healthcare system in Indonesia.
IPMG represents the view of its members in discussions with the Government and other stakeholders about healthcare issues. IPMG maintains close contact and works closely with the Government, parliamentarians, academics, professional bodies, health organizations, the media and other partners in a continuous effort to improve Indonesia’s healthcare systems.
IPMG members and their headquarters continue to invest in research and development to bring to Indonesia the latest innovations in medicines that are safe and on par with international standards of quality. The safety and quality of our medicines have been proven through extensive clinical trials at our certified, state-of-the-art manufacturing facilities.
While striving to provide Indonesians full access to innovative medicines, IPMG members respect and comply with the prevailing laws and regulations in Indonesia, and keep their business in line with the highest ethical marketing codes. IPMG member companies also actively engage with local communities, support local health programs and carry out public education campaigns on diseases and health promotion.
Meanwhile, as an active member of KADIN, MIAP, and IFPMA, IPMG reaches out to the public and other stakeholders through regular issuance of press releases and position papers as well as through IPMG websites.
So far, IPMG members have introduced more than 900 state-of-the-art products into Indonesia to treat cancers, infectious diseases, cardiovascular diseases and other diseases. IPMG members today employ more than 11,000 Indonesians in their operations.

Mission Statement
IPMG seeks to play an important role as a partner to the Government of Indonesia in improving the healthcare system through the core strengths of its members, i.e. medical innovation and manufacturing of products that meet international standards of pharmaceutical quality and safety.

IPMG members respect and comply with the prevailing medical laws and regulations and uphold the highest ethical marketing codes. 

IPMG members are also actively involved in the community through health programs and public education campaigns on diseases.
About the Pharmaceutical Industry

Over the years pharmaceutical companies have continuously come up with new drugs to control and treat diseases as well as mitigate patients’ suffering. New diseases, however, have also continuously been identified. Therefore, IPMG members are committed to finding new drugs to treat them.

According to the Ministry of Health data in 2013, there were 206 pharmaceutical companies operating in Indonesia. The national average annual growth in prescription drugs sales is estimated at 12%-13%. 

Today, Indonesia’s pharmaceutical market value is estimated at USD 6.24 billion, reflecting pharmaceutical spend of USD 26 per capita per annum, with national companies controlling 75% of the market share. Ethical drugs contributed 55%, or USD 3.2 billion, to the total market, while the over-the-counter drugs made up the remaining 41%, or USD 2.2 billion.

However, the country’s ethical drugs industry is expected to see a decline in sales next year as more people will be turning to generics under the National Health Insurance (JKN) scheme, a government program which promoted the prescription of generic medicines. Another contributing factor is the expected increase in production cost due to the fact that 95% of raw materials are still imported.

In 2015, the country’s pharmaceutical sales-to-GDP ratio is forecasted to shrink to 0.57% despite an expected increase in pharmaceutical sales to USD 6.89 billion from USD 6.18 billion in 2014.  Pharmaceutical sales per capita is estimated to go up to USD 26.9 billion in 2015 from USD 24.5 billion in 2014. The pharmaceutical sales-to-health spending ratio is predicted to drop from USD 21.4 billion in 2014 to USD 20.5 billion next year.


Other Health Data


About Us
Chairman Message
Who We Are
Organization Structure
IPMG Members
» Hainan Province, Hengda Health and Korean Yuanchen Signs Strategic Cooperation Agreement
Boao, China - In the evening on March 29, Hong Kong listed company New Media (HK.708) (to be changed into Hengda Health Industry Co., Ltd.) announced that it has signed a strategic investment cooperation framework agreement with the Management Committee of the pioneer district of the international medical tourism in Lecheng, Boao, Hainan Province; and Korean Yuanchen Medical Cosmetology Group on March 28 to establish an international medical cosmetology and anti-aging center at the above mentioned pioneer district. An original report from Sina Leju follows.

More » 
» BPOM seizes Rp 150 m worth of fake drugs distributed online
The National Drug and Food Monitoring Agency (BPOM), in conducting its fifth Pangea Operation, has seized thousands of illegal and fake drugs marketed online.

BPOM chairwoman Lucky S.Slamet said Monday that during the operation, her agency had identified 83 websites that allegedly distributed illegal and fake drugs, up from the 30 sites it uncovered during the previous Pangea Operation in 2011. Read full article here .
More » 
April 2019

Copyright © 2013 International Pharmaceutical Manufacturers Group